ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.69 CNY | 0.00% |
|
+3.50% | +6.95% |
| Apr. 24 | Huahai Pharmaceutical Gets Approval to Market Busulfan Injection | MT |
| Apr. 19 | Tranche Update on Zhejiang Huahai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 14, 2023. | CI |
| Sales 2023 * | 8.47B 1.17B | Sales 2024 * | 9.84B 1.36B | Capitalization | 23.09B 3.19B |
|---|---|---|---|---|---|
| Net income 2023 * | 978M 135M | Net income 2024 * | 1.18B 162M | EV / Sales 2023 | - |
| Net Debt 2023 * | 1.9B 262M | Net Debt 2024 * | 2.54B 350M | EV / Sales 2024 * | 2.61 x |
| P/E ratio 2023 * |
23.2
x | P/E ratio 2024 * |
19.4
x | Employees | 7,682 |
| Yield 2023 * |
1.55% | Yield 2024 * |
1.08% | Free-Float | 56.44% |
More Fundamentals
* Assessed data
More news
| 1 week | +3.50% | ||
| Current month | +21.63% | ||
| 1 month | +18.50% | ||
| 3 months | +25.02% | ||
| 6 months | +3.70% | ||
| Current year | +6.95% |
1 week
14.91
15.88
1 month
12.5215.88
Current year
10.7115.88
1 year
10.7120.10
3 years
10.7127.46
5 years
10.7145.70
10 years
7.4145.70
| Managers | Title | Age | Since |
|---|---|---|---|
Mei Zhang
DFI | Director of Finance/CFO | 48 | 08-05-31 |
Bao Hua Chen
PSD | President | 62 | 07-03-31 |
Si Jia Guo
BRD | Director/Board Member | 61 | 17-04-20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bao Hua Chen
PSD | President | 62 | 07-03-31 |
Yong Hua Zhu
BRD | Director/Board Member | 59 | - |
Hu Gen Wang
CHM | Chairman | 75 | 10-04-14 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.57% | 2 M€ | -19.10% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 15.69 | 0.00% | 10,049,280 |
| 24-04-23 | 15.69 | -0.13% | 12,887,840 |
| 24-04-22 | 15.71 | +3.36% | 25,030,520 |
| 24-04-19 | 15.2 | +1.06% | 12,975,610 |
| 24-04-18 | 15.04 | -0.79% | 14,494,400 |
End-of-day quote Shanghai S.E., April 23, 2024
More quotes
ZHEJIANGHUAHAIPHARMACEUTICALCO., LTD is a China-based company, principally engaged in the manufacture and distribution of active pharmaceutical ingredients (APIs), intermediates and preparations. The Company's main products are classified as -pril series, -sartan series and preparations, including irbesartan tablets, paroxetine hydrochloride tablets, risperidone tablets, fosinopril sodium tablets, as well as irbesartan and hydrochlorothinzide tablets, among others. The Company also provides related technical support services. The Company distributes its products in domestic and overseas markets.
Sector
Pharmaceuticals
Calendar
2024-04-29
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
15.69
CNY
Average target price
16.37
CNY
Spread / Average Target
+4.31%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +6.95% | 3.19B | |
| +25.61% | 660B | |
| +25.87% | 562B | |
| -5.24% | 358B | |
| +16.49% | 322B | |
| +8.28% | 297B | |
| +7.09% | 219B | |
| -9.12% | 196B | |
| +5.01% | 199B | |
| -8.75% | 149B |
- Stock Market
- Equities
- 600521 Stock
